Medindia

X

Victory Pharma Completes Acquisition of Assets of MiddleBrook Pharmaceuticals

Tuesday, August 3, 2010 Drug News J E 4
Advertisement
Company Expands Product Portfolio, Adds Drug Delivery Technology

SAN DIEGO, Aug. 3 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") today  announced  that it has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals, Inc. (OTCQB: MBRKQ).

Through the acquisition, Victory Pharma has expanded its product portfolio with the addition of anti-infective  products  MOXATAG® and KEFLEX® as well as the PULSYS® drug delivery technology platform.  The product additions complement Victory's current products, such as NAPRELAN®, which the company markets to primary care and specialist physicians.

"This acquisition reflects our strategy of leveraging our existing commercial infrastructure to expand our portfolio of marketed products," said Matt Heck, president and chief executive officer of  Victory  Pharma.  "The addition of  these products balances our portfolio nicely, as NAPRELAN's highest period of utilization is in the spring and summer, while MOXATAG's utilization peaks during the flu season.  And we believe MOXATAG will substantially benefit from our management team's prior, successful experience marketing anti-infective products."

MOXATAG is the only FDA-approved, once-daily formulation of amoxicillin, and is indicated for the treatment of tonsillitis and/or pharyngitis.  MOXATAG utilizes PULSYS technology to deliver drug at set intervals over a 24 hour period, whereas other amoxicillin products require multiple times daily dosing. Reduced dosing frequency can improve therapy compliance, which is potentially important given patient non-compliance is widely-recognized as the primary reason for antibiotic therapy failure 1,2,3, and non-compliant patients have been shown to have a 175 percent greater chance of infection recurrence 4.

About MiddleBrook Pharmaceuticals

MiddleBrook  Pharmaceuticals, Inc. (OTCQB:  MBRKQ) is a company that focused on commercializing anti-infective products to fulfill unmet medical needs. MiddleBrook developed a proprietary delivery technology, PULSYS®, that enables  the pulsatile delivery, or delivery in rapid bursts, of certain drugs. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

About Victory Pharma

Founded in 2003, Victory Pharma Inc. is a privately-held, specialty pharmaceutical company headquartered in San Diego focused on acquiring, developing, and marketing products to treat pain and related conditions. Victory markets its lead product, NAPRELAN® (naproxen sodium) Controlled-Release Tablets, and other pain products to pain management specialists, rheumatologists, orthopedic surgeons, and selected primary care physicians through its physician office-based field sales force.  Further information regarding Victory Pharma is available at www.victorypharma.com.

NAPRELAN® is a trademark of Elan Corporation, plc.

SOURCE Victory Pharma, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Surveyed Physicians Anticipate an Increase in Thei...
S
RBC Life Sciences Reports 16% Second Quarter Sales...